AstraZeneca has announced a $15bn investment in China by 2030 to expand manufacturing and R&D. The new investment will build on China’s established leadership in science and manufacturing, as well as existing collaborations between the healthcare ecosystems of China and the UK. AstraZeneca will increase its capabilities in the areas of cell therapy and radioconjugates, thereby advancing its portfolio of treatments for cancer as well as haematological and autoimmune diseases. Following its acquisition of Gracell Biotechnologies in 2024, AstraZeneca will soon become the first major global biopharmaceutical company with end-to-end cell therapy capabilities in China. The investment is aligned with China’s Healthy China 2030 and ‘Common Health’ agenda for increased accessibility in innovative medicines.